Professor Yiwu He currently serves as Vice President of Eastern Institute of Technology, Ningbo (EIT), overseeing general administration, campus planning, and construction.  Prior to this appointment, Prof. Yiwu He served many senior executive roles, including Senior Advisor to the President and Chief Innovation Officer of The University of Hong Kong, Chairman of the Board and Managing Director of HKU Innovation Holdings Limited, and Board Member of the University of Hong Kong-Shenzhen Hospital. He has also served as deputy director and senior program officer at the Bill & Melinda Gates Foundation, Global Head of R&D and Special Assistant to the Chairman at BGI and CEO of BGI USA, Global Head of Human Biomarker Centers at GlaxoSmithKline, the board director of P4 Medicine Institute, USA, as well as the chair professor at The University of Science and Technology of China.

Professor Yiwu He possesses extensive international collaboration experience spanning government, academia, and industry. He has led and participated in high-tech investment projects, as well as global medical research and disease control initiatives involving governments, non-governmental organizations, and institutions such as the World Health Organization. During his tenure at the Gates Foundation, Professor Yiwu He was responsible for multiple global health programs including diagnostics, drug, and vaccine development. He managed the foundation's investments in the areas including HIV, TB, Pneumonia, Enteric Diarrhea, Polio and other infectious diseases. In addition, he established and managed multiple R&D programs in China under the directions of Bill Gates. His efforts in China helped the advancements of R&D of its biotech industry and particularly led to the large-scale vaccine productions with modern international standards that assured China's first and second vaccines pre-qualified by the World Health Organization. While working in the pharmaceutical industry, Professor Yiwu He contributed to the development of several innovative drugs, including five new drugs or vaccines that have been approved for market in the U.S. and other regions.

Professor Yiwu He holds a Bachelor’s degree from Fudan University, a Ph.D. degree from Boston University, and an Executive Master of Business Administration from Duke University, USA. He also conducted postdoctoral research at Harvard Medical School.